BOLT BIOTHERAPEUTICS INC (BOLT)

US0977021049 - Common Stock

0.7355  +0 (+0.07%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (6/20/2024, 3:30:01 PM)

0.7355

+0 (+0.07%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-25.9%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap28.04M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BOLT Daily chart

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 94 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of immunotherapies for the treatment of cancer. Its proprietary Boltbody ISAC (immune-stimulating antibody conjugate) platform technology combines tumor-targeting antibodies with immune-stimulating linker payloads to create productive anti-tumor immune responses. This approach creates products that work with a patient’s own immune system, resulting in anti-cancer efficacy with tolerability. Its first Boltbody ISAC is its BDC-1001 program, targeting a tumor antigen, HER2. BDC-1001 completed a dose-escalation trial and is advancing into multiple Phase II clinical trials. BDC-3042, its Dectin-2 agonist antibody program, is being developed to repolarize critical cells in the tumor microenvironment known as tumor-associated macrophages (TAMs) by targeting cell-surface receptors.

Company Info

BOLT BIOTHERAPEUTICS INC

900 Chesapeake Drive

Redwood City CALIFORNIA 94063

P: 16506659295

CEO: Randall C. Schatzman

Employees: 94

Website: https://boltbio.com/

BOLT News

News Image5 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such...

News Image21 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such...

News Imagea month ago - InvestorPlaceThe Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows

Explore key stocks with analyst uncertainty to avoid amid contrasting global market highs and risky downgrades.

News Imagea month ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such...

News Imagea month ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such...

News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning!

BOLT Twits

Here you can normally see the latest stock twits on BOLT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example